Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Neurofibrosarcoma × pexidartinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 1 Recurrence 1 Neurofibrosarcoma 1 Neoplasms 1 Neoplasm Metastasis 1 Leukemia, Myeloid, Acute 1 Glioblastoma 1 Gastrointestinal Stromal Tumors 1 Breast Neoplasms 1

Interventions

pazopanib 2 Sirolimus 2 temsirolimus 1 selinexor 1 pexidartinib 1 pembrolizumab 1 liposomal doxorubicin 1 lentiviral minigene vaccine of COVID-19 coronavirus 1 STA 9090 1 Proton Therapy 1 Ifosfamide 1 HhAntag691 1 Doxorubicin 1 Docetaxel 1 AZD 6244 1 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02584647 2025-03-21

PLX3397

Columbia University

Phase 1/2 Terminated

39 enrolled 13 charts

Sarcoma, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡